{"disease":{"id":"hematological-diseases","name":"hematological diseases"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05505760","title":"Testing Content Delivery Models for MomConnect","phase":"NA","overall_status":"UNKNOWN","enrollment_count":8867,"lead_sponsor_name":"IDinsight","has_results":false},{"nct_id":"NCT05002582","title":"Carbapenem-resistant Organisms (CRO) Screening From Rectal Swabs in Patients With Hematological Diseases in China","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT03815175","title":"XIENCE 28 USA Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":1605,"lead_sponsor_name":"Abbott Medical Devices","has_results":true},{"nct_id":"NCT06277479","title":"Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study","phase":"","overall_status":"COMPLETED","enrollment_count":1262,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03854318","title":"Longitudinal Studies of Patient With FPDMM","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT06113601","title":"Assessment of Admission to the ICU of Onco-hematological Patients.","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"University Hospital A Coruña","has_results":false},{"nct_id":"NCT02661035","title":"Allo HSCT Using RIC for Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06281496","title":"AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03745287","title":"A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT06548958","title":"A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05929092","title":"TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07451236","title":"CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Chang Yingjun","has_results":false},{"nct_id":"NCT05329649","title":"Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}